Ligand Pharmaceuticals Incorporated Common Stock Earnings Dividend

Ligand Pharmaceuticals Incorporated Common Stock’s revenue jumped 14.09% since last year same period to $51.72Mn in the Q1 2026. On a quarterly growth basis, Ligand Pharmaceuticals Incorporated Common Stock has generated -13.31% fall in its revenue since last 3-months.

Ligand Pharmaceuticals Incorporated Common Stock’s net profit jumped 68.56% since last year same period to $-13.35Mn in the Q1 2026. On a quarterly growth basis, Ligand Pharmaceuticals Incorporated Common Stock has generated -129.8% fall in its net profits since last 3-months.

Ligand Pharmaceuticals Incorporated Common Stock’s net profit margin jumped 72.45% since last year same period to -25.8% in the Q1 2026. On a quarterly growth basis, Ligand Pharmaceuticals Incorporated Common Stock has generated -134.38% fall in its net profit margins since last 3-months.

Ligand Pharmaceuticals Incorporated Common Stock’s price-to-earnings ratio after this Q1 2026 earnings stands at 33.02.

Ligand Pharmaceuticals Incorporated Common Stock’s earning per share (EPS) estimates for the current quarter stand at 1.21 - a 23.47% jump from last quarter’s estimates.

Ligand Pharmaceuticals Incorporated Common Stock’s earning per share (EPS) estimates for the current year stand at 1.21.

Ligand Pharmaceuticals Incorporated Common Stock’s earning per share (EPS) fell -150.38% since last year same period to -0.67 in the Q1 2026. This indicates that the Ligand Pharmaceuticals Incorporated Common Stock has generated -150.38% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ligand Pharmaceuticals Incorporated Common Stock’s return on assets (ROA) stands at 0.05.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ligand Pharmaceuticals Incorporated Common Stock’s return on equity (ROE) stands at 0.17.